Every 8-K that Foghorn Therapeutics Inc. (FHTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow FHTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FHTX filings page.
Foghorn Therapeutics reported Q2 2026 results alongside a broad pipeline update in chromatin biology. Lead asset FHD‑909, a first‑in‑class selective SMARCA2 inhibitor partnered with Lilly, is advancing through a first‑in‑human Phase 1 dose‑escalation trial focused on SMARCA4‑mutant non‑small cell lung cancer. Pending successful Phase 1 dose escalation, Foghorn and Lilly anticipate evaluating FHD‑909 in combination studies in NSCLC with pembrolizumab. Selective EP300 degraders for hematologic malignancies and prostate cancer and a selective CBP degrader (FHT‑171) for ER+ breast and EP300‑mutant cancers are progressing preclinically, with INDs targeted in 2027. A novel oral small molecule in immunology and inflammation and a first‑in‑class ARID1B degrader for ARID1A‑mutant solid tumors are also being advanced toward 2027 INDs, while the CBP program timeline has been delayed by an operational issue at a third‑party contract research organization.
Collaboration revenue for the quarter was $16.1 million versus $7.6 million a year earlier, driven by a cumulative catch‑up adjustment under the Lilly collaboration. Research and development expenses were $18.5 million and general and administrative expenses were $6.4 million. Net loss was $7.2 million compared with $17.9 million in Q2 2025. Cash, cash equivalents and marketable securities totaled $167.6 million at June 30, 2026, providing cash runway into the first half of 2028.
Foghorn Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on June 24, 2026. Stockholders elected three Class III directors—Douglas Cole, M.D., Balkrishan (Simba) Gill, Ph.D., and B. Lynne Parshall—to serve until the 2029 annual meeting. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. On an advisory basis, stockholders approved the compensation of the company’s named executive officers and supported holding future advisory votes on executive compensation every one year. A total of 58,713,922 shares were entitled to vote, with 51,708,896 shares present or represented by proxy.
Foghorn Therapeutics reported first quarter 2026 results alongside a broad pipeline update in oncology. Collaboration revenue was $3.3 million for the three months ended March 31, 2026, while research and development expenses were $18.3 million and general and administrative expenses were $6.6 million.
The company recorded a net loss of $19.9 million for the quarter, or $0.29 per share, compared with a net loss of $18.8 million a year earlier. As of March 31, 2026, Foghorn held $183.6 million in cash, cash equivalents and marketable securities, which it expects will fund operations into the first half of 2028.
Operationally, Foghorn highlighted progress for its lead SMARCA2 inhibitor FHD-909, now in an ongoing Phase 1 trial in SMARCA4-mutant cancers under its collaboration with Lilly, and presented preclinical data showing promising combination effects with anti-PD-1 therapy and KRAS inhibitors. The company also advanced selective degrader programs targeting CBP, EP300 and ARID1B toward IND-enabling studies and in vivo proof of concept, underscoring a diversified pipeline in difficult-to-treat cancers.
Foghorn Therapeutics Inc. filed an 8-K describing new preclinical data and an updated investor presentation focused on its chromatin biology pipeline. The company highlighted FHD-909, a selective SMARCA2 inhibitor partnered with Lilly, which in mouse models produced complete and durable tumor regression and apparent anti-tumor immune memory when combined with an anti-PD-1 antibody.
Foghorn also reported strong preclinical activity for its selective CBP degrader FHT-171 in heavily pretreated ER+ breast cancer models, and selective EP300 degraders that outperformed dual CBP/EP300 inhibitor inobrodib in multiple myeloma models while sparing platelets. Cereblon-based selective ARID1B degraders showed robust target degradation and transcriptional effects in ARID1A‑mutant cancer settings. The company notes a major collaboration with Lilly and states it had $158.9 million in cash and equivalents as of December 31, 2025, plus $50 million of gross proceeds from a January 2026 financing, supporting a cash runway into the first half of 2028.
Foghorn Therapeutics reported 2025 results and outlined its oncology pipeline progress and financing. Collaboration revenue rose to $30.9 million from $22.6 million, while research and development expenses fell to $85.5 million from $94.5 million. General and administrative expenses edged down to $27.6 million from $28.4 million, and net loss improved to $74.3 million from $86.6 million, or $1.18 per share versus $1.58 in 2024.
As of December 31, 2025, Foghorn held $158.9 million in cash, cash equivalents and marketable securities. A $50 million registered direct financing completed in January 2026 at $6.71 per share, with warrants struck at $13.42 and $20.13, extends cash runway into the first half of 2028. The company highlighted its Phase 1 SMARCA2 inhibitor FHD‑909 partnered with Lilly, plus selective CBP, EP300 and ARID1B degrader programs tracking toward IND‑enabling work in 2026.
Foghorn Therapeutics Inc. appointed Ryan D. Maynard as Chief Financial Officer, effective February 23, 2026. He will serve as the company’s principal financial and accounting officer, succeeding interim CFO Jeff Sacher.
Maynard brings more than 25 years of executive finance experience at biopharmaceutical and healthcare companies, including prior CFO roles at Cara Therapeutics, LetsGetChecked, Blade Therapeutics, and Rigel Pharmaceuticals. His employment terms include a $510,000 annual base salary, eligibility for an annual performance bonus targeted at 40% of base salary, a $90,000 signing bonus, and a stock option to purchase 400,000 Foghorn common shares under the 2020 Equity Incentive Plan. The option vests 25% on the first anniversary of grant and the remaining 75% in equal quarterly installments over the following 12 quarters, subject to continued employment.
The company issued a press release highlighting Maynard’s track record in capital markets, strategic transactions, and commercial planning, as well as his ongoing board role at Iovance Biotherapeutics. Foghorn reiterated its focus on developing oncology medicines targeting the chromatin regulatory system and referenced forward-looking statements about its pipeline, clinical trials, and cash runway.
Foghorn Therapeutics entered into securities purchase agreements with life sciences investors to raise approximately $50.0 million in gross proceeds through a registered offering. The company is issuing 2,030,314 shares of common stock and pre-funded warrants to purchase 5,421,250 shares of common stock, sold together with Series 1 and Series 2 warrants to purchase an aggregate of 7,451,564 additional shares.
The pre-funded warrants are exercisable immediately at $0.0001 per share for 20 years. Series 1 warrants are exercisable at $13.42 per share and expire on June 30, 2027, while Series 2 warrants are exercisable at $20.13 per share and expire on December 31, 2030. The securities were priced at $6.71 per share of common stock (or $6.7099 per pre-funded warrant), with no underwriter or placement agent, under an effective Form S-3 shelf registration, and the offering is expected to close on January 13, 2026.
Foghorn Therapeutics Inc. announced that its Board of Directors has appointed Jeff Sacher as Treasurer and interim Chief Financial Officer, effective immediately. The company continues to search for a permanent CFO. Sacher will provide interim CFO services through Danforth Advisors, LLC, which already has a consulting agreement with the company, and Foghorn will pay Danforth an agreed hourly rate and reimburse expenses.
Sacher is a 35-year veteran of the biotechnology and investment banking industries and has served as a CFO at Danforth since May 2022. He previously worked as a senior investment banker at several firms and holds an M.B.A. from the Kellogg School of Management at Northwestern University and a B.A. in biology from Cornell University. The company states he has no family relationships with its executive officers or directors, and there are no other arrangements underlying his appointment beyond those described.
Foghorn Therapeutics Inc. furnished an investor presentation as Exhibit 99.1 under Item 7.01 (Regulation FD). The presentation is dated November 2025 and is intended for meetings with or presentations to investors. The materials are being furnished, not filed, under the Exchange Act and are not subject to Section 18 liabilities, nor incorporated by reference except as expressly stated.
Foghorn Therapeutics (FHTX) furnished a press release announcing financial results for the quarter ended September 30, 2025. The materials were provided as Exhibit 99.1.
The company also disclosed that Chief Financial Officer Kristian Humer will resign effective November 14, 2025. The resignation was described as to pursue other opportunities and not due to any disagreement regarding operations, policies, practices, financial controls, or audit procedures. Foghorn has begun a search for a replacement.
Additionally, Foghorn furnished an investor presentation dated November 2025 as Exhibit 99.2.
Foghorn Therapeutics (FHTX) filed an 8-K announcing pipeline updates for its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs. On October 30, 2025, the company hosted a conference call and webcast to review these updates, and furnished the related presentation as Exhibit 99.1 under Regulation FD.
Foghorn also issued a press release on the same date, attached as Exhibit 99.2 and incorporated by reference. The furnished materials are not deemed filed for liability purposes under Section 18 of the Exchange Act. The disclosure includes customary forward-looking statements language referencing clinical trials, product candidates, and risk factors in the company’s most recent Form 10-K.
Foghorn Therapeutics Inc. furnished a new investor presentation dated September 2025 as an exhibit to a current report. The company plans to use this presentation in meetings and presentations with investors, offering an overview of its business and outlook in a slide format.
The investor materials are provided under a Regulation FD disclosure, which means they are being made available to the public to ensure fair access to information. The company states that the presentation is being furnished, not filed, so it is not subject to certain legal liabilities under the securities laws unless specifically incorporated into other documents.